Lars B Abrahmsen

USPTO Granted Patents = 18 (Patent Applications = 3)

CIPO Patents = 7 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 3.7

ph-index = 6

Forward Citations = 244(Granted Patents)

Location History:

Bromma, SE (2005 - 2019)
Stockholm, SE (1992 - 2020)
Valhallavagen, SE (2018 - 2023)

Company Filing History:

General Electric Company

Pharmacia & Upjohn Aktiebolag

patents

8. 1 out of 371

Ge Healthcare Bio-sciences Ab

patents

where one patent can have more than one assignee

Years Active: 1992-2023

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11633507 - HER2 binders (2023-04-25),

2. 10894097 - HER2 binders (2021-01-19),

3. 10562955 - Polypeptides (2020-02-18),

4. 10329331 - Polypeptides (2019-06-25),

5. 10159760 - HER2 binders (2018-12-25),

6. 9975943 - Polypeptides (2018-05-22),

7. 9211344 - Polypeptides (2015-12-15),

8. 9175067 - Immunoglobulin G Fc region binding polypeptide (2015-11-03),

9. 7226601 - Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate (2007-06-05),

10. 7226595 - Modified Chimeric superantigens and their use (2007-06-05),

11. 6962694 - Cytolysis of target cells by superantigen conjugates inducing T-cell activation (2005-11-08),

12. 5876968 - Dimer of molecular variant of apolipoprotein and processes for the (1999-03-02),

13. 5763256 - Serine protease variants having peptide ligase activity (1998-06-09),

14. 5736512 - Serine protease variants having peptide ligase activity (1998-04-07),

15. 5629173 - Methods of use of serine protease variants having peptide ligase activity (1997-05-13),

Title: Innovator Spotlight: Lars B Abrahmsen – A Leader in HER2 Imaging Agents

Introduction: Lars B Abrahmsen is a prominent inventor based in Stockholm, Sweden, known for his significant contributions to the field of biomedical imaging. With an impressive portfolio of 18 patents, he has made remarkable advancements in the development of imaging agents targeting the HER2 protein, which plays a crucial role in various cancers.

Latest Patents: Among his latest innovations, Lars B Abrahmsen has developed pioneering imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator. These agents are specifically designed to bind to HER2 or its variants, providing an essential tool for imaging in clinical applications. His work emphasizes methods for preparing and utilizing these imaging agents, enhancing diagnostic capabilities in oncology.

Career Highlights: Lars's career is marked by significant contributions while working with notable companies in the biotechnology sector. Notably, he has served at Affibody AB and Genentech, Inc., where he has leveraged his expertise to propel advancements in medical imaging techniques and therapeutic applications.

Collaborations: Throughout his career, Lars B Abrahmsen has collaborated with esteemed colleagues, including Elin Gunneriusson and John P Burnier. These collaborations have played a pivotal role in enriching his research and fostering innovative approaches in the realm of imaging technologies.

Conclusion: Lars B Abrahmsen stands out as a leading figure in the development of HER2 imaging agents, showcasing his inventive spirit and dedication to improving diagnostic methodologies. His continued work and patent contributions represent a bright future for advancements in cancer diagnostics, ultimately benefiting patients and the medical community at large.

This text is generated by artificial intelligence and may not be accurate.